

SEATTLE SPERM BANK
Attn: Dr. Jeffrey Olliffe

4915 25th Ave NE, Suite 204W Seattle, WA 98105 Phone: (206) 588-1484 Fax: (206) 466-4696 NPI: 1306838271 Report Date: 09/05/2018 DONOR 12361

MALE

DONOR 12361 DOB:

Ethnicity: Mixed or Other

Caucasian
Sample Type: EDTA Blood

Date of Collection: 08/28/2018 Date Received: 08/29/2018 Date Tested: 09/05/2018 Barcode: 11004212280599 Accession ID: CSLA4XARP6RFKYK Indication: Egg or sperm donor FEMALE N/A

**POSITIVE: CARRIER** 

# Foresight™ Carrier Screen

#### ABOUT THIS TEST

The **Counsyl Foresight Carrier Screen** utilizes sequencing, maximizing coverage across all DNA regions tested, to help you learn about your chance to have a child with a genetic disease.

#### **RESULTS SUMMARY**

Risk Details	DONOR 12361	Partner
Panel Information	Foresight Carrier Screen Universal Panel (175 conditions tested)	N/A
POSITIVE: CARRIER	■ CARRIER*	The reproductive risk presented is
Smith-Lemli-Opitz Syndrome	NM_001360.2(DHCR7):c.964-1G>C	based on a hypothetical pairing with a partner of the same ethnic group. Carrier testing should be considered. See "Next Steps".
Reproductive Risk: 1 in 200 Inheritance: Autosomal Recessive	(aka IVS8-1G>C) heterozygote	

<sup>\*</sup>Carriers generally do not experience symptoms.

No disease-causing mutations were detected in any other gene tested. A complete list of all conditions tested can be found on page 6.

#### **CLINICAL NOTES**

None

#### **NEXT STEPS**

- Carrier testing should be considered for the diseases specified above for the patient's partner, as both parents must be carriers before a child is at high risk of developing the disease.
- Genetic counseling is recommended and patients may wish to discuss any positive results with blood relatives, as there is an increased chance that they are also carriers.



Report Date: 09/05/2018

CIPIENT MALE

M BANK DONOR 12361

frey Olliffe DOB:

Caucasian

Barcode: 11004212280599

Ethnicity: Mixed or Other

FEMALE N/A

# POSITIVE: CARRIER Smith-Lemli-Opitz Syndrome

Gene: DHCR7 | Inheritance Pattern: Autosomal Recessive

Reproductive risk: 1 in 200 Risk before testing: 1 in 9,800

Patient	DONOR 12361	No partner tested
Result	<b>⊕</b> Carrier	N/A
Variant(s)	NM_001360.2(DHCR7):c.964-1G>C(aka IVS8-1G>C) heterozygote	N/A
Methodology	Sequencing with copy number analysis	N/A
Interpretation	This individual is a carrier of Smith-Lemli-Opitz syndrome. Carriers generally do not experience symptoms. The IVS8-1G>C mutation is associated with the severe form of this disease.	N/A
Detection rate	>99%	N/A
Exons tested	NM_001360:3-9.	N/A

### What is Smith-Lemli-Opitz Syndrome?

Smith-Lemli-Opitz syndrome, or SLO syndrome, is an inherited disorder in which the body's ability to make cholesterol is impaired due to a deficient enzyme. Cholesterol is critical for the structure of cells, and is necessary for normal fetal development. It also plays an important role in the production of hormones and digestive acids. In addition to low cholesterol levels, SLO syndrome also causes toxic byproducts of cholesterol production to build up throughout the body, further disrupting growth and development.

In children with little or no ability to make cholesterol, symptoms are severe. These infants are commonly born with an abnormally small head, cleft palate, and weak muscle tone. They often have difficulty feeding because they lack the sucking reflex or have an abnormally small stomach that causes persistent vomiting. Some have extra fingers or toes as well as the typical fused second and third toes on both feet. Male infants may have deformed or underdeveloped genitalia.

Infants with the severe form of SLO syndrome grow slowly and 90% have moderate to severe mental disability. Severely affected infants may also have heart defects and problems with their kidneys, causing death in the first months of life.

Some children are born with a milder form of the condition in which the body can produce some cholesterol. Symptoms may include developmental delays, feet with the second and third toes fused together, slow growth, and short stature. These children generally learn to walk and talk and can acquire other skills, although they can rarely live independently as adults. Adults with the disease often show aggressive behavior.

Symptoms of the disease can vary from person to person. Some affected people have only minor symptoms of the condition.

## How common is Smith-Lemli-Opitz Syndrome?

Smith-Lemli-Opitz syndrome affects an estimated 1 in 20,000 to 60,000 people. This disease is more common in those of European ancestry, particularly those in Slovakia and the Czech Republic. It is very rare among people of African and Asian descent.



Report Date: 09/05/2018

MALE

DONOR 12361

DOB:

Ethnicity: Mixed or Other

Caucasian

**Barcode:** 11004212280599

FEMALE N/A

#### How is Smith-Lemli-Opitz Syndrome treated?

There is no cure for SLO syndrome, but its symptoms can be addressed. The primary treatment is to supplement the person's diet with large amounts of dietary cholesterol, either in the form of purified cholesterol or in foods such as egg yolks and cream. This has been shown to improve symptoms. Early intervention and therapy helps with speech and physical disabilities. Medication may treat symptoms such as vomiting, constipation, and gastroesophageal reflux. Surgery and orthotics can help muscle spasms and improve mobility.

Because the condition can cause extreme sun sensitivity, people with SLO syndrome should always wear sunblock, sunglasses, and appropriate clothing when they go outdoors.

### What is the prognosis for a person with Smith-Lemli-Opitz Syndrome?

Although serious internal malformations can lead to early death, with good nutrition and medical care many people with SLO syndrome can have a normal lifespan. Mental disability typically prevents people with this disease from living independently.



Report Date: 09/05/2018

MALE **DONOR 12361 DOB:** 

Ethnicity: Mixed or Other

Caucasian

Barcode: 11004212280599

FEMALE N/A

## Methods and Limitations

DONOR 12361 [Foresight Carrier Screen]: Sequencing with copy number analysis, spinal muscular atrophy, and analysis of homologous regions.

## Sequencing with copy number analysis

High-throughput sequencing and read depth-based copy number analysis are used to analyze the listed exons, as well as selected intergenic and intronic regions, of the genes in the Conditions Tested section of the report. The region of interest (ROI) of the test comprises these regions, in addition to the 20 intronic bases flanking each exon. In a minority of cases where genomic features (e.g., long homopolymers) compromise calling fidelity, the affected intronic bases are not included in the ROI. The ROI is sequenced to high coverage and the sequences are compared to standards and references of normal variation. More than 99% of all bases in the ROI are sequenced at greater than the minimum read depth. Mutations may not be detected in areas of lower sequence coverage. Small insertions and deletions may not be as accurately determined as single nucleotide variants. Genes that have closely related pseudogenes may be addressed by a different method. *CFTR* and *DMD* testing includes analysis for both large (exon-level) deletions and duplications with an average sensitivity of 99%, while other genes are only analyzed for large deletions with a sensitivity of >75%. However, the sensitivity may be higher for selected founder deletions. If *GJB2* is tested, two large upstream deletions which overlap *GJB6* and affect the expression of *GJB2*, del(*GJB6*-D13S1830) and del(*GJB6*-D13S1854), are also analyzed. Mosaicism or somatic variants present at low levels may not be detected. If detected, these may not be reported.

Detection rates are determined by using literature to estimate the fraction of disease alleles, weighted by frequency, that the methodology is unable to detect. Detection rates only account for analytical sensitivity and certain variants that have been previously described in the literature may not be reported if there is insufficient evidence for pathogenicity. Detection rates do not account for the disease-specific rates of de novo mutations.

All variants that are a recognized cause of the disease will be reported. In addition, variants that have not previously been established as a recognized cause of disease may be identified. In these cases, only variants classified as "likely" pathogenic are reported. Likely pathogenic variants are described elsewhere in the report as "likely to have a negative impact on gene function". Likely pathogenic variants are evaluated and classified by assessing the nature of the variant and reviewing reports of allele frequencies in cases and controls, functional studies, variant annotation and effect prediction, and segregation studies. Exon level duplications are assumed to be in tandem and are classified according to their predicted effect on the reading frame. Benign variants, variants of uncertain significance, and variants not directly associated with the intended disease phenotype are not reported. Curation summaries of reported variants are available upon request.

## Spinal muscular atrophy

Targeted copy number analysis is used to determine the copy number of exon 7 of the *SMN1* gene relative to other genes. Other mutations may interfere with this analysis. Some individuals with two copies of *SMN1* are carriers with two *SMN1* genes on one chromosome and a *SMN1* deletion on the other chromosome. This is more likely in individuals who have 2 copies of the *SMN1* gene and are positive for the g.27134T>G SNP, which affects the reported residual risk; Ashkenazi Jewish or Asian patients with this genotype have a high post-test likelihood of being carriers for SMA and are reported as carriers. The g.27134T>G SNP is only reported in individuals who have 2 copies of *SMN1*.

## Analysis of homologous regions

A combination of high-throughput sequencing, read depth-based copy number analysis, and targeted genotyping is used to determine the number of functional gene copies and/or the presence of selected loss of function mutations in certain genes that have homology to other regions. The precise breakpoints of large deletions in these genes cannot be determined, but are estimated from copy number analysis. High numbers of pseudogene copies may interfere with this analysis.

If *CYP21A2* is tested, patients who have one or more additional copies of the *CYP21A2* gene and a loss of function mutation may not actually be a carrier of 21-hydroxylase-deficient congenital adrenal hyperplasia (CAH). Because the true incidence of non-classic CAH is unknown, the residual carrier and reproductive risk numbers on the report are only based on published incidences for classic CAH. However, the published prevalence of non-classic CAH is highest in individuals of Ashkenazi Jewish, Hispanic, Italian, and Yugoslav descent. Therefore, the residual and reproductive risks are likely an underestimate of overall chances for 21-hydroxylase-deficient CAH, especially in the aforementioned populations, as they do not account for non-classic CAH. If *HBA11HBA2* are tested, some individuals with four alpha globin genes may be carriers, with three genes on one chromosome and a deletion on the other chromosome. This and similar, but rare, carrier states, where complementary changes exist in both the gene and a pseudogene, may not be detected by the assay.



Report Date: 09/05/2018

MALE **DONOR 12361** 

DOB: Ethnicity: Mixed or Other

Caucasian

Barcode: 11004212280599

FEMALE N/A

#### Limitations

In an unknown number of cases, nearby genetic variants may interfere with mutation detection. Other possible sources of diagnostic error include sample mix-up, trace contamination, bone marrow transplantation, blood transfusions and technical errors. This test is designed to detect and report germline alterations. While somatic variants present at low levels may be detected, these may not be reported. If more than one variant is detected in a gene, additional studies may be necessary to determine if those variants lie on the same chromosome or different chromosomes. The test does not fully address all inherited forms of intellectual disability, birth defects and genetic disease. A family history of any of these conditions may warrant additional evaluation. Furthermore, not all mutations will be identified in the genes analyzed and additional testing may be beneficial for some patients. For example, individuals of African, Southeast Asian, and Mediterranean ancestry are at increased risk for being carriers for hemoglobinopathies, which can be identified by CBC and hemoglobin electrophoresis or HPLC (ACOG Practice Bulletin No. 78. Obstet. Gynecol. 2007;109:229-37).

This test was developed and its performance characteristics determined by Counsyl, Inc. It has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA does not require this test to go through premarket review. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. These results are adjunctive to the ordering physician's evaluation. CLIA Number: #05D1102604.

LABORATORY DIRECTOR

Hyunseok Kang

H. Peter Kang, MD, MS, FCAP

Report content approved by Saurav Guha, PhD, FACMG on Sep 5, 2018



SEATTLE SPERM BANK

Attn: Dr. Jeffrey Olliffe NPI: 1306838271

Report Date: 09/05/2018

MALE

**DONOR 12361** 

DOB:

Caucasian

Caucasian 98%.

Barcode: 11004212280599

Ethnicity: Mixed or Other

FEMALE N/A

# **Conditions Tested**

**11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia - Gene:** CYP11B1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000497:1-9. **Detection Rate:** Mixed or Other Caucasian 94%.

21-hydroxylase-deficient Congenital Adrenal Hyperplasia - Gene: CYP21A2. Autosomal Recessive. Analysis of homologous regions. Variants (13): CYP21A2 deletion, CYP21A2 duplication, CYP21A2 triplication, G111Vfs\*21, I173N, L308Ffs\*6, P31L, Q319\*, Q319\*+CYP21A2dup, R357W, V281L, [I237N;V238E;M240K], c.293-13C>G. Detection Rate: Mixed or Other Caucasian 96%.

**6-pyruvoyl-tetrahydropterin Synthase Deficiency** - **Gene:** PTS. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000317:1-6. **Detection Rate:** Mixed or Other Caucasian >99%.

**ABCC8-related Hyperinsulinism - Gene:** ABCC8. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000352:1-39. **Detection Rate:** Mixed or Other Caucasian >99%

Adenosine Deaminase Deficiency - Gene: ADA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000022:1-12. Detection Rate: Mixed or Other Caucasian >99%.

**Alpha Thalassemia** - **Genes**: HBA1, HBA2. Autosomal Recessive. Analysis of homologous regions. **Variants** (13): -(alpha)20.5, --BRIT, --MEDI, --MEDII, --SEA, -- THAI or --FIL, -alpha3.7, -alpha4.2, HBA1+HBA2 deletion, Hb Constant Spring, anti3.7, anti4.2. del HS-40. **Detection Rate**: Unknown due to rarity of disease.

**Alpha-mannosidosis** - **Gene**: MAN2B1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000528:1-23. **Detection Rate**: Mixed or Other Caucasian >99%.

**Alpha-sarcoglycanopathy** - **Gene:** SGCA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000023:1-9. **Detection Rate:** Mixed or Other Caucasian >99%

Alstrom Syndrome - Gene: ALMS1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_015120:1-23. Detection Rate: Mixed or Other

**AMT-related Glycine Encephalopathy** - **Gene**: AMT. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000481:1-9. **Detection Rate**: Mixed or Other Caucasian >99%.

**Andermann Syndrome** - **Gene:** SLC12A6. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_133647:1-25. **Detection Rate:** Mixed or Other Caucasian >99%

**Argininemia** - **Gene**: ARG1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_001244438:1-8. **Detection Rate**: Mixed or Other Caucasian 97%.

Argininosuccinic Aciduria - Gene: ASL. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_001024943:1-16. Detection Rate: Mixed or Other

**ARSACS** - **Gene**: SACS. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_014363:2-10. **Detection Rate**: Mixed or Other Caucasian 99%.

**Aspartylglycosaminuria** - **Gene:** AGA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000027:1-9. **Detection Rate:** Mixed or Other

**Ataxia with Vitamin E Deficiency - Gene**: TTPA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000370:1-5. **Detection Rate**: Mixed or Other Caucasian >99%.

Ataxia-telangiectasia - Gene: ATM. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000051:2-63. Detection Rate: Mixed or Other Caucasian 98%.

**ATP7A-related Disorders** - **Gene**: ATP7A. X-linked Recessive. Sequencing with copy number analysis. **Exons**: NM\_000052:2-23. **Detection Rate**: Mixed or Other Caucasian 96%.

**Autosomal Recessive Osteopetrosis Type 1** - **Gene**: TCIRG1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_006019:2-20. **Detection Rate**: Mixed or Other Caucasian >99%.

**Bardet-Biedl Syndrome, BBS1-related** - **Gene**: BBS1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_024649:1-17. **Detection Rate**: Mixed or Other Caucasian >99%.

Bardet-Biedl Syndrome, BBS10-related - Gene: BBS10. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_024685:1-2. Detection Rate: Mixed or Other Caucasian >99%.

**Bardet-Biedl Syndrome, BBS12-related - Gene**: BBS12. Autosomal Recessive. Sequencing with copy number analysis. **Exon**: NM\_152618:2. **Detection Rate**: Mixed or Other Caucasian >99%.

**Bardet-Biedl Syndrome**, **BBS2-related** - **Gene**: BBS2. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_031885:1-17. **Detection Rate**: Mixed or Other Caucasian >99%.

**Beta-sarcoglycanopathy** - **Gene**: SGCB. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000232:1-6. **Detection Rate**: Mixed or Other Caucasian >99%.

**Biotinidase Deficiency** - **Gene**: BTD. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000060:1-4. **Detection Rate**: Mixed or Other Caucasian >99%.

**Bloom Syndrome** - Gene: BLM. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000057:2-22. **Detection Rate:** Mixed or Other Caucasian >99%.

Calpainopathy - Gene: CAPN3. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000070:1-24. Detection Rate: Mixed or Other Caucasian >99%. Canavan Disease - Gene: ASPA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000049:1-6. Detection Rate: Mixed or Other

Carbamoylphosphate Synthetase I Deficiency - Gene: CPS1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_001875:1-38. Detection Rate: Mixed or Other Caucasian >99%.

Carnitine Palmitoyltransferase IA Deficiency - Gene: CPT1A. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_001876:2-19. Detection Rate: Mixed or Other Caucasian >99%.

Carnitine Palmitoyltransferase II Deficiency - Gene: CPT2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000098:1-5. Detection Rate: Mixed or Other Caucasian >99%.

**Cartilage-hair Hypoplasia** - **Gene:** RMRP. Autosomal Recessive. Sequencing with copy number analysis. **Exon:** NR\_003051:1. **Detection Rate:** Mixed or Other Caucasian >99%.

**Cerebrotendinous Xanthomatosis - Gene:** CYP27A1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000784:1-9. **Detection Rate:** Mixed or Other Caucasian >99%.

**Citrullinemia Type 1 - Gene:** ASS1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000050:3-16. **Detection Rate:** Mixed or Other Caucasian >99%.

**CLN3-related Neuronal Ceroid Lipofuscinosis - Gene**: CLN3. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_001042432:2-16. **Detection Rate**: Mixed or Other Caucasian >99%.

**CLN5-related Neuronal Ceroid Lipofuscinosis - Gene**: CLN5. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_006493:1-4. **Detection Rate**: Mixed or Other Caucasian >99%.

CLN6-related Neuronal Ceroid Lipofuscinosis - Gene: CLN6. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_017882:1-7. Detection Rate: Mixed or Other Caucasian >99%.

**Cohen Syndrome** - **Gene**: VPS13B. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_017890:2-62. **Detection Rate**: Mixed or Other Caucasian 97%.

**COL4A3-related Alport Syndrome - Gene:** COL4A3. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000091:1-52. **Detection Rate:** Mixed or Other Caucasian 97%.

**COL4A4-related Alport Syndrome - Gene:** COL4A4. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000092:2-48. **Detection Rate:** Mixed or Other Caucasian 98%.

Congenital Disorder of Glycosylation Type Ia - Gene: PMM2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000303:1-8. Detection Rate: Mixed or Other Caucasian >99%.

**Congenital Disorder of Glycosylation Type Ib** - **Gene**: MPI. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_002435:1-8. **Detection Rate**: Mixed or Other Caucasian >99%.

**Congenital Disorder of Glycosylation Type Ic** - **Gene**: ALG6. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_013339:2-15. **Detection Rate**: Mixed or Other Caucasian >99%.



Mixed or Other Caucasian 98%.

RESULTS RECIPIENT

SEATTLE SPERM BANK
Attn: Dr. Jeffrey Olliffe
NPI: 1306838271

Report Date: 09/05/2018

MALE

**DONOR 12361** 

DOB: Ethnicity: Mixed or Other

Caucasian

Barcode: 11004212280599

FEMALE N/A

**Congenital Finnish Nephrosis** - **Gene:** NPHS1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_004646:1-29. **Detection Rate:** Mixed or Other Caucasian >99%.

**Costeff Optic Atrophy Syndrome - Gene**: OPA3. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_025136:1-2. **Detection Rate**: Mixed or Other Caucasian >99%.

Cystic Fibrosis - Gene: CFTR. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000492:1-27. IVS8-5T allele analysis is only reported in the presence of the R117H mutation. Detection Rate: Mixed or Other Caucasian >99%. Cystinosis - Gene: CTNS. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_004937:3-12. Detection Rate: Mixed or Other Caucasian >99%. D-bifunctional Protein Deficiency - Gene: HSD17B4. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000414:1-24. Detection Rate:

**Delta-sarcoglycanopathy** - **Gene**: SGCD. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000337:2-9. **Detection Rate**: Mixed or Other Caucasian 99%.

**Dysferlinopathy** - **Gene**: DYSF. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_001130987:1-56. **Detection Rate**: Mixed or Other Caucasian 98%.

**Dystrophinopathy (Including Duchenne/Becker Muscular Dystrophy)** - **Gene:** DMD. X-linked Recessive. Sequencing with copy number analysis. **Exons:** 

**ERCC6-related Disorders - Gene:** ERCC6. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000124:2-21. **Detection Rate:** Mixed or Other Caucasian 90%

NM\_004006:1-79. Detection Rate: Mixed or Other Caucasian >99%.

**ERCC8-related Disorders** - **Gene**: ERCC8. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000082:1-12. **Detection Rate**: Mixed or Other Caucasian 95%.

**EVC-related Ellis-van Creveld Syndrome** - **Gene**: EVC. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_153717:1-21. **Detection Rate**: Mixed or Other Caucasian 96%.

**EVC2-related Ellis-van Creveld Syndrome** - **Gene**: EVC2. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_147127:1-22. **Detection Rate**: Mixed or Other Caucasian >99%.

**Fabry Disease** - **Gene**: GLA. X-linked Recessive. Sequencing with copy number analysis. **Exons**: NM\_000169:1-7. **Detection Rate**: Mixed or Other Caucasian 98%. **Familial Dysautonomia** - **Gene**: IKBKAP. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_003640:2-37. **Detection Rate**: Mixed or Other Caucasian >99%.

**Familial Mediterranean Fever** - **Gene**: MEFV. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000243:1-10. **Detection Rate**: Mixed or Other Caucasian >99%.

**Fanconi Anemia Complementation Group A** - **Gene**: FANCA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000135:1-43. **Detection Rate**: Mixed or Other Caucasian 92%.

**Fanconi Anemia Type C - Gene**: FANCC. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000136:2-15. **Detection Rate**: Mixed or Other Caucasian >99%.

**FKRP-related Disorders - Gene:** FKRP. Autosomal Recessive. Sequencing with copy number analysis. **Exon:** NM\_024301:4. **Detection Rate:** Mixed or Other Caucasian >99%.

**FKTN-related Disorders** - **Gene**: FKTN. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_001079802:3-11. **Detection Rate**: Mixed or Other Caucasian >99%.

**Galactokinase Deficiency - Gene:** GALK1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000154:1-8. **Detection Rate:** Mixed or Other Caucasian >99%

Galactosemia - Gene: GALT. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000155:1-11. Detection Rate: Mixed or Other Caucasian >99%. Gamma-sarcoglycanopathy - Gene: SGCG. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000231:2-8. Detection Rate: Mixed or Other Caucasian 88%.

**Gaucher Disease** - **Gene**: GBA. Autosomal Recessive. Analysis of homologous regions. **Variants (10)**: D409V, D448H, IVS2+1G>A, L444P, N370S, R463C, R463H, R496H, V394L, p.L29Afs\*18. **Detection Rate**: Mixed or Other Caucasian 60%.

GJB2-related DFNB1 Nonsyndromic Hearing Loss and Deafness - Gene: GJB2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_004004:1-2. Detection Rate: Mixed or Other Caucasian >99%.

**GLB1-related Disorders** - **Gene**: GLB1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000404:1-16. **Detection Rate**: Mixed or Other Caucasian >99%.

**GLDC-related Glycine Encephalopathy** - **Gene**: GLDC. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000170:1-25. **Detection Rate**: Mixed or Other Caucasian 94%.

**Glutaric Acidemia Type 1** - **Gene**: GCDH. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000159:2-12. **Detection Rate**: Mixed or Other Caucasian >99%.

**Glycogen Storage Disease Type Ia** - **Gene:** G6PC. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000151:1-5. **Detection Rate:** Mixed or Other Caucasian >99%.

**Glycogen Storage Disease Type Ib** - **Gene:** SLC37A4. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_001164277:3-11. **Detection Rate:** Mixed or Other Caucasian >99%.

**Glycogen Storage Disease Type III - Gene:** AGL. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000642:2-34. **Detection Rate:** Mixed or Other Caucasian >99%.

**GNPTAB-related Disorders - Gene**: GNPTAB. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_024312:1-21. **Detection Rate**: Mixed or Other Caucasian >99%.

**GRACILE Syndrome** - **Gene:** BCS1L. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_004328:3-9. **Detection Rate:** Mixed or Other Caucasian >99%.

**HADHA-related Disorders** - **Gene**: HADHA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000182:1-20. **Detection Rate**: Mixed or Other Caucasian >99%.

Hb Beta Chain-related Hemoglobinopathy (Including Beta Thalassemia and Sickle Cell Disease) - Gene: HBB. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000518:1-3. Detection Rate: Mixed or Other Caucasian >99%.

**Hereditary Fructose Intolerance - Gene**: ALDOB. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000035:2-9. **Detection Rate**: Mixed or Other Caucasian >99%.

Herlitz Junctional Epidermolysis Bullosa, LAMA3-related - Gene: LAMA3. Autosomal Recessive. Sequencing with copy number analysis. Exons:

NM\_000227:1-38. **Detection Rate**: Mixed or Other Caucasian >99%. **Herlitz Junctional Epidermolysis Bullosa, LAMB3-related** - **Gene**: LAMB3. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000228:2-23. **Detection Rate**: Mixed or Other Caucasian >99%.

**Herlitz Junctional Epidermolysis Bullosa, LAMC2-related** - **Gene**: LAMC2. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_005562:1-23. **Detection Rate**: Mixed or Other Caucasian >99%.

**Hexosaminidase A Deficiency (Including Tay-Sachs Disease)** - **Gene:** HEXA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000520:1-14. **Detection Rate:** Mixed or Other Caucasian >99%.

**HMG-CoA Lyase Deficiency - Gene**: HMGCL. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000191:1-9. **Detection Rate**: Mixed or Other Caucasian 98%.

**Holocarboxylase Synthetase Deficiency** - **Gene**: HLCS. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000411:4-12. **Detection Rate**: Mixed or Other Caucasian >99%.

Homocystinuria Caused by Cystathionine Beta-synthase Deficiency - Gene: CBS. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000071:3-17. Detection Rate: Mixed or Other Caucasian >99%.

**Hydrolethalus Syndrome** - **Gene**: HYLS1. Autosomal Recessive. Sequencing with copy number analysis. **Exon**: NM\_001134793:3. **Detection Rate**: Mixed or Other Caucasian >99%.

**Hypophosphatasia, Autosomal Recessive** - **Gene:** ALPL. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000478:2-12. **Detection Rate:** Mixed or Other Caucasian >99%.

**Inclusion Body Myopathy 2** - **Gene**: GNE. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_001128227:1-12. **Detection Rate**: Mixed or Other Caucasian >99%.

**Isovaleric Acidemia** - **Gene:** IVD. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_002225:1-12. **Detection Rate:** Mixed or Other Caucasian >99%.

**Joubert Syndrome 2 - Gene:** TMEM216. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_001173990:1-5. **Detection Rate:** Mixed or Other Caucasian >99%.



SEATTLE SPERM BANK

Attn: Dr. Jeffrey Olliffe
NPI: 1306838271

Report Date: 09/05/2018

MALE

**DONOR 12361** 

DOB: Ethnicity: Mixed or Other

Caucasian

**Barcode:** 11004212280599

FEMALE N/A

**KCNJ11-related Familial Hyperinsulinism** - **Gene**: KCNJ11. Autosomal Recessive. Sequencing with copy number analysis. **Exon**: NM\_000525:1. **Detection Rate**: Mixed or Other Caucasian >99%.

**Krabbe Disease** - **Gene**: GALC. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000153:1-17. **Detection Rate**: Mixed or Other Caucasian >99%. **LAMA2-related Muscular Dystrophy** - **Gene**: LAMA2. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000426:1-65. **Detection Rate**:

Mixed or Other Caucasian >99%.

**Leigh Syndrome, French-Canadian Type** - **Gene**: LRPPRC. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_133259:1-38. **Detection Rate**: Mixed or Other Caucasian >99%.

**Lipoamide Dehydrogenase Deficiency** - **Gene**: DLD. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000108:1-14. **Detection Rate**: Mixed or Other Caucasian >99%.

**Lipoid Congenital Adrenal Hyperplasia** - Gene: STAR. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000349:1-7. **Detection Rate:** Mixed or Other Caucasian >99%.

**Lysosomal Acid Lipase Deficiency - Gene:** LIPA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000235:2-10. **Detection Rate:** Mixed or Other Caucasian >99%.

**Maple Syrup Urine Disease Type 1B** - **Gene:** BCKDHB. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_183050:1-10. **Detection Rate:** Mixed or Other Caucasian >99%.

**Maple Syrup Urine Disease Type Ia** - **Gene:** BCKDHA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000709:1-9. **Detection Rate:** Mixed or Other Caucasian >99%.

**Maple Syrup Urine Disease Type II - Gene**: DBT. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_001918:1-11. **Detection Rate**: Mixed or Other Caucasian 96%.

Medium Chain Acyl-CoA Dehydrogenase Deficiency - Gene: ACADM. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000016:1-12. Detection Rate: Mixed or Other Caucasian >99%.

**Megalencephalic Leukoencephalopathy with Subcortical Cysts** - **Gene:** MLC1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** 

NM\_015166:2-12. **Detection Rate**: Mixed or Other Caucasian >99%. **Metachromatic Leukodystrophy** - **Gene**: ARSA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000487:1-8. **Detection Rate**: Mixed or Other

**Methylmalonic Acidemia, cblA Type** - **Gene**: MMAA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_172250:2-7. **Detection Rate**: Mixed or Other Caucasian >99%.

Methylmalonic Acidemia, cblB Type - Gene: MMAB. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_052845:1-9. Detection Rate: Mixed or Other Caucasian >99%.

Methylmalonic Aciduria and Homocystinuria, cblC Type - Gene: MMACHC. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_015506:1-4. Detection Rate: Mixed or Other Caucasian >99%.

MKS1-related Disorders - Gene: MKS1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_017777:1-18. Detection Rate: Mixed or Other Caucasian >99%.

**Mucolipidosis III Gamma** - **Gene:** GNPTG. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_032520:1-11. **Detection Rate:** Mixed or Other Caucasian >99%.

**Mucolipidosis IV** - **Gene:** MCOLN1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_020533:1-14. **Detection Rate:** Mixed or Other Caucasian >99%

**Mucopolysaccharidosis Type I** - **Gene**: IDUA. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000203:1-14. **Detection Rate**: Mixed or Other Caucasian >99%.

**Mucopolysaccharidosis Type II** - **Gene:** IDS. X-linked Recessive. Sequencing with copy number analysis. **Exons:** NM\_000202:1-9. **Detection Rate:** Mixed or Other Caucasian 88%.

**Mucopolysaccharidosis Type IIIA - Gene**: SGSH. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000199:1-8. **Detection Rate**: Mixed or Other Caucasian >99%.

**Mucopolysaccharidosis Type IIIB** - **Gene**: NAGLU. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000263:1-6. **Detection Rate**: Mixed or Other Caucasian >99%.

**Mucopolysaccharidosis Type IIIC** - **Gene**: HGSNAT. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_152419:1-18. **Detection Rate**: Mixed or Other Caucasian >99%.

**Muscle-eye-brain Disease** - **Gene:** POMGNT1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_017739:2-22. **Detection Rate:** Mixed or Other Caucasian 96%.

**MUT-related Methylmalonic Acidemia** - **Gene**: MUT. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000255:2-13. **Detection Rate**: Mixed or Other Caucasian >99%.

MYO7A-related Disorders - Gene: MYO7A. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000260:2-49. Detection Rate: Mixed or Other Caucasian >99%.

**NEB-related Nemaline Myopathy** - **Gene:** NEB. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_001271208:3-80,117-183. **Detection Rate:** Mixed or Other Caucasian 92%.

**Nephrotic Syndrome, NPHS2-related - Gene:** NPHS2. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_014625:1-8. **Detection Rate:** Mixed or Other Caucasian >99%.

**Niemann-Pick Disease Type C - Gene**: NPC1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000271:1-25. **Detection Rate**: Mixed or Other Caucasian >99%.

**Niemann-Pick Disease Type C2** - **Gene:** NPC2. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_006432:1-5. **Detection Rate:** Mixed or Other Caucasian >99%.

Niemann-Pick Disease, SMPD1-associated - Gene: SMPD1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000543:1-6. Detection Rate: Mixed or Other Caucasian >99%.

**Nijmegen Breakage Syndrome** - **Gene**: NBN. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_002485:1-16. **Detection Rate**: Mixed or Other Caucasian >99%.

**Northern Epilepsy** - **Gene:** CLN8. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_018941:2-3. **Detection Rate:** Mixed or Other Caucasian >99%.

**Ornithine Transcarbamylase Deficiency - Gene**: OTC. X-linked Recessive. Sequencing with copy number analysis. **Exons**: NM\_000531:1-10. **Detection Rate**: Mixed or Other Caucasian 97%.

**PCCA-related Propionic Acidemia - Gene:** PCCA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000282:1-24. **Detection Rate:** Mixed or Other Caucasian 95%.

PCCB-related Propionic Acidemia - Gene: PCCB. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_001178014:1-16. Detection Rate: Mixed or Other Caucasian >99%.

**PCDH15-related Disorders** - **Gene:** PCDH15. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_033056:2-33. **Detection Rate:** Mixed or Other Caucasian 93%.

**Pendred Syndrome** - **Gene:** SLC26A4. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000441:2-21. **Detection Rate:** Mixed or Other Caucasian >99%.

**Peroxisome Biogenesis Disorder Type 3** - **Gene**: PEX12. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000286:1-3. **Detection Rate**: Mixed or Other Caucasian >99%.

**Peroxisome Biogenesis Disorder Type 4** - Gene: PEX6. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000287:1-17. **Detection Rate**: Mixed or Other Caucasian 97%.

**Peroxisome Biogenesis Disorder Type 5 - Gene**: PEX2. Autosomal Recessive. Sequencing with copy number analysis. **Exon**: NM\_000318:4. **Detection Rate**: Mixed or Other Caucasian >99%.

**Peroxisome Biogenesis Disorder Type 6** - **Gene**: PEX10. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_153818:1-6. **Detection Rate**: Mixed or Other Caucasian >99%.

**PEX1-related Zellweger Syndrome Spectrum - Gene:** PEX1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000466:1-24. **Detection Rate:** Mixed or Other Caucasian >99%.

**Phenylalanine Hydroxylase Deficiency** - **Gene:** PAH. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000277:1-13. **Detection Rate:** Mixed or Other Caucasian >99%.

PKHD1-related Autosomal Recessive Polycystic Kidney Disease - Gene: PKHD1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_138694:2-67. Detection Rate: Mixed or Other Caucasian >99%.



SEATTLE SPERM BANK

Attn: Dr. Jeffrey Olliffe
NPI: 1306838271
Penert Date: 09/05/20

Report Date: 09/05/2018

MALE

DONOR 12361 DOB:

Ethnicity: Mixed or Other

Caucasian

**Barcode:** 11004212280599

**Polyglandular Autoimmune Syndrome Type 1** - **Gene**: AIRE. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000383:1-14. **Detection Rate**: Mixed or Other Caucasian >99%.

Pompe Disease - Gene: GAA. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000152:2-20. Detection Rate: Mixed or Other Caucasian 98%. PPT1-related Neuronal Ceroid Lipofuscinosis - Gene: PPT1. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000310:1-9. Detection Rate: Mixed or Other Caucasian >99%.

**Primary Carnitine Deficiency** - **Gene**: SLC22A5. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_003060:1-10. **Detection Rate**: Mixed or Other Caucasian >99%.

**Primary Hyperoxaluria Type 1** - **Gene**: AGXT. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000030:1-11. **Detection Rate**: Mixed or Other Caucasian >99%.

**Primary Hyperoxaluria Type 2** - **Gene:** GRHPR. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_012203:1-9. **Detection Rate:** Mixed or Other Caucasian >99%.

**Primary Hyperoxaluria Type 3** - **Gene**: HOGA1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_138413:1-7. **Detection Rate**: Mixed or Other Caucasian >99%.

**PROP1-related Combined Pituitary Hormone Deficiency** - **Gene**: PROP1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_006261:1-3. **Detection Rate**: Mixed or Other Caucasian >99%.

**Pycnodysostosis** - **Gene**: CTSK. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000396:2-8. **Detection Rate**: Mixed or Other Caucasian >99%. **Pyruvate Carboxylase Deficiency** - **Gene**: PC. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_022172:2-21. **Detection Rate**: Mixed or Other Caucasian >99%.

Rhizomelic Chondrodysplasia Punctata Type 1 - Gene: PEX7. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000288:1-10. Detection Rate: Mixed or Other Caucasian >99%.

**RTEL1-related Disorders** - **Gene:** RTEL1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_032957:2-35. **Detection Rate:** Mixed or Other Caucasian >99%.

Salla Disease - Gene: SLC17A5. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_012434:1-11. Detection Rate: Mixed or Other Caucasian 98%. Sandhoff Disease - Gene: HEXB. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000521:1-14. Detection Rate: Mixed or Other Caucasian >99%.

Segawa Syndrome - Gene: TH. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000360:1-13. Detection Rate: Mixed or Other Caucasian >99%. Short Chain Acyl-CoA Dehydrogenase Deficiency - Gene: ACADS. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000017:1-10. Detection Rate: Mixed or Other Caucasian >99%.

**Sjogren-Larsson Syndrome** - **Gene**: ALDH3A2. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000382:1-10. **Detection Rate**: Mixed or Other Caucasian 97%.

**Smith-Lemli-Opitz Syndrome** - **Gene:** DHCR7. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_001360:3-9. **Detection Rate:** Mixed or Other Caucasian >99%.

**Spastic Paraplegia Type 15** - **Gene**: ZFYVE26. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_015346:2-42. **Detection Rate**: Mixed or Other Caucasian >99%.

**Spinal Muscular Atrophy** - **Gene**: SMN1. Autosomal Recessive. Spinal muscular atrophy. **Variant** (1): SMN1 copy number. **Detection Rate**: Mixed or Other Caucasian 95%.

**Spondylothoracic Dysostosis** - **Gene**: MESP2. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_001039958:1-2. **Detection Rate**: Mixed or Other Caucasian >99%.

FEMALE

N/A

Sulfate Transporter-related Osteochondrodysplasia - Gene: SLC26A2. Autosomal Recessive. Sequencing with copy number analysis. Exons: NM\_000112:2-3. Detection Rate: Mixed or Other Caucasian >99%.

**TGM1-related Autosomal Recessive Congenital Ichthyosis** - **Gene**: TGM1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000359:2-15. **Detection Rate**: Mixed or Other Caucasian >99%.

**TPP1-related Neuronal Ceroid Lipofuscinosis - Gene**: TPP1. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000391:1-13. **Detection Rate**: Mixed or Other Caucasian >99%.

**Tyrosinemia Type I** - **Gene**: FAH. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000137:1-14. **Detection Rate**: Mixed or Other Caucasian >99%.

**Tyrosinemia Type II** - **Gene:** TAT. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000353:2-12. **Detection Rate:** Mixed or Other Caucasian >99%.

**USH1C-related Disorders** - **Gene**: USH1C. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_153676:1-27. **Detection Rate**: Mixed or Other Caucasian >99%.

**USH2A-related Disorders** - **Gene**: USH2A. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_206933:2-72. **Detection Rate**: Mixed or Other Caucasian 94%.

**Usher Syndrome Type 3** - **Gene:** CLRN1. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_174878:1-3. **Detection Rate:** Mixed or Other Caucasian >99%.

**Very Long Chain Acyl-CoA Dehydrogenase Deficiency** - **Gene**: ACADVL. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000018:1-20. **Detection Rate**: Mixed or Other Caucasian >99%.

**Wilson Disease** - **Gene**: ATP7B. Autosomal Recessive. Sequencing with copy number analysis. **Exons**: NM\_000053:1-21. **Detection Rate**: Mixed or Other Caucasian >99%. **X-linked Adrenoleukodystrophy** - **Gene**: ABCD1. X-linked Recessive. Sequencing with copy number analysis. **Exons**: NM\_000033:1-6. **Detection Rate**: Mixed or Other Caucasian 77%.

**X-linked Alport Syndrome** - **Gene:** COL4A5. X-linked Recessive. Sequencing with copy number analysis. **Exons:** NM\_000495:1-51. **Detection Rate:** Mixed or Other Caucasian 95%.

X-linked Congenital Adrenal Hypoplasia - Gene: NR0B1. X-linked Recessive. Sequencing with copy number analysis. Exons: NM\_000475:1-2. Detection Rate: Mixed or Other Caucasian 99%.

X-linked Juvenile Retinoschisis - Gene: RS1. X-linked Recessive. Sequencing with copy number analysis. Exons: NM\_000330:1-6. Detection Rate: Mixed or Other Caucasian 98%.

X-linked Myotubular Myopathy - Gene: MTM1. X-linked Recessive. Sequencing with copy number analysis. Exons: NM\_000252:2-15. Detection Rate: Mixed or Other Caucasian 98%.

X-linked Severe Combined Immunodeficiency - Gene: IL2RG. X-linked Recessive. Sequencing with copy number analysis. Exons: NM\_000206:1-8. Detection Rate: Mixed or Other Caucasian >99%.

**Xeroderma Pigmentosum Group A** - **Gene:** XPA. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_000380:1-6. **Detection Rate:** Mixed or Other Caucasian >99%.

**Xeroderma Pigmentosum Group C** - **Gene:** XPC. Autosomal Recessive. Sequencing with copy number analysis. **Exons:** NM\_004628:1-16. **Detection Rate:** Mixed or Other Caucasian 97%.



RESULTS RECIPIENT

SEATTLE SPERM BANK

Attn: Dr. Jeffrey Olliffe

NPI: 1306838271

Report Date: 09/05/2018

MALE DONOR 12361

DOB: Ethnicity: Mixed or Other

Caucasian

Barcode: 11004212280599

FEMALE N/A

# Risk Calculations

Below are the risk calculations for all conditions tested. Since negative results do not completely rule out the possibility of being a carrier, the **residual risk** represents the patient's post-test likelihood of being a carrier and the **reproductive risk** represents the likelihood the patient's future children could inherit each disease. These risks are inherent to all carrier screening tests, may vary by ethnicity, are predicated on a negative family history and are present even after a negative test result. Inaccurate reporting of ethnicity may cause errors in risk calculation. The reproductive risk presented is based on a hypothetical pairing with a partner of the same ethnic group.

†Indicates a positive result. See the full clinical report for interpretation and details.

Disease	DONOR 12361 Residual Risk	Reproductive Risk
11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia	1 in 3,800	< 1 in 1,000,000
21-hydroxylase-deficient Congenital Adrenal Hyperplasia	1 in 1,400	1 in 310,000
6-pyruvoyl-tetrahydropterin Synthase Deficiency	< 1 in 50,000	< 1 in 1,000,000
ABCC8-related Hyperinsulinism	1 in 11,000	< 1 in 1,000,000
Adenosine Deaminase Deficiency	1 in 22,000	< 1 in 1,000,000
Alpha Thalassemia	Alpha globin status: aa/aa.	Not calculated
Alpha-mannosidosis	1 in 35,000	< 1 in 1,000,000
Alpha-sarcoglycanopathy	1 in 45,000	< 1 in 1,000,000
Alstrom Syndrome	< 1 in 50,000	< 1 in 1,000,000
AMT-related Glycine Encephalopathy	1 in 22,000	< 1 in 1,000,000
Andermann Syndrome	< 1 in 50,000	< 1 in 1,000,000
Argininemia	< 1 in 17,000	< 1 in 1,000,000
Argininosuccinic Aciduria	1 in 13,000	< 1 in 1,000,000
ARSACS	< 1 in 44,000	< 1 in 1,000,000
Aspartylglycosaminuria	< 1 in 50,000	< 1 in 1,000,000
Ataxia with Vitamin E Deficiency	< 1 in 50,000	< 1 in 1,000,000
Ataxia-telangiectasia	1 in 8,200	< 1 in 1,000,000
ATP7A-related Disorders	< 1 in 1,000,000	1 in 600,000
Autosomal Recessive Osteopetrosis Type 1	1 in 35,000	< 1 in 1,000,000
Bardet-Biedl Syndrome, BBS1-related	1 in 16,000	< 1 in 1,000,000
Bardet-Biedl Syndrome, BBS10-related	1 in 16,000	< 1 in 1,000,000
Bardet-Biedl Syndrome, BBS12-related	< 1 in 50,000	< 1 in 1,000,000
Bardet-Biedl Syndrome, BBS2-related	< 1 in 50,000	< 1 in 1,000,000
Beta-sarcoglycanopathy	< 1 in 50,000	< 1 in 1,000,000
Biotinidase Deficiency	1 in 13,000	1 in 650,000
Bloom Syndrome	< 1 in 50,000	< 1 in 1,000,000
Calpainopathy	1 in 13,000	< 1 in 1,000,000
Canavan Disease	< 1 in 31,000	< 1 in 1,000,000
Carbamoylphosphate Synthetase I Deficiency	< 1 in 57,000	< 1 in 1,000,000
Carnitine Palmitoyltransferase IA Deficiency	< 1 in 50,000	< 1 in 1,000,000
Carnitine Palmitoyltransferase II Deficiency	< 1 in 50,000	< 1 in 1,000,000
Cartilage-hair Hypoplasia	< 1 in 50,000	< 1 in 1,000,000
Cerebrotendinous Xanthomatosis	1 in 11,000	< 1 in 1,000,000
Citrullinemia Type 1	1 in 12,000	< 1 in 1,000,000
CLN3-related Neuronal Ceroid Lipofuscinosis	1 in 22,000	< 1 in 1,000,000
CLN5-related Neuronal Ceroid Lipofuscinosis	< 1 in 50,000	< 1 in 1,000,000
CLN6-related Neuronal Ceroid Lipofuscinosis	1 in 43,000	< 1 in 1,000,000
Cohen Syndrome	< 1 in 15,000	< 1 in 1,000,000
COL4A3-related Alport Syndrome	1 in 6,200	< 1 in 1,000,000
COL4A4-related Alport Syndrome	1 in 12,000	< 1 in 1,000,000
Congenital Disorder of Glycosylation Type Ia	1 in 16,000	< 1 in 1,000,000
Congenital Disorder of Glycosylation Type Ib	< 1 in 50,000	< 1 in 1,000,000
Congenital Disorder of Glycosylation Type Ic	< 1 in 50,000	< 1 in 1,000,000
Congenital Finnish Nephrosis	< 1 in 50,000	< 1 in 1,000,000
Costeff Optic Atrophy Syndrome	< 1 in 50,000	< 1 in 1,000,000
Cystic Fibrosis	1 in 2,700	1 in 290,000
Cystinosis	1 in 22,000	< 1 in 1,000,000
D-bifunctional Protein Deficiency	1 in 9,000	< 1 in 1,000,000



Report Date: 09/05/2018

MALE

DONOR 12361

DOB: Ethnicity: Mixed or Other

Caucasian

Barcode: 11004212280599

FEMALE N/A

Disease	DONOR 12361 Residual Risk	Reproductive Risk
Delta-sarcoglycanopathy	< 1 in 40,000	< 1 in 1,000,000
Dysferlinopathy	1 in 11,000	< 1 in 1,000,000
Dystrophinopathy (Including Duchenne/Becker Muscular Dystrophy)	Not calculated	Not calculated
ERCC6-related Disorders	1 in 26,000	< 1 in 1,000,000
ERCC8-related Disorders	< 1 in 9,900	< 1 in 1,000,000
EVC-related Ellis-van Creveld Syndrome	1 in 7,500	< 1 in 1,000,000
EVC2-related Ellis-van Creveld Syndrome	< 1 in 50,000	< 1 in 1,000,000
Fabry Disease	< 1 in 1,000,000	1 in 80,000
Familial Dysautonomia	< 1 in 50,000	< 1 in 1,000,000
Familial Mediterranean Fever	< 1 in 50,000	< 1 in 1,000,000
Fanconi Anemia Complementation Group A	1 in 2,800	< 1 in 1,000,000
Fanconi Anemia Type C	1 in 16,000	< 1 in 1,000,000
FKRP-related Disorders	1 in 16,000	< 1 in 1,000,000
FKTN-related Disorders	< 1 in 50,000	< 1 in 1,000,000
Galactokinase Deficiency	1 in 10,000	< 1 in 1,000,000
Galactosemia	1 in 8,600	< 1 in 1,000,000
Gamma-sarcoglycanopathy	1 in 3,000	< 1 in 1,000,000
Gaucher Disease	1 in 280	1 in 120,000
GJB2-related DFNB1 Nonsyndromic Hearing Loss and Deafness	1 in 3,200	1 in 420,000
GLB1-related Disorders	1 in 19,000	< 1 in 1,000,000
GLDC-related Glycine Encephalopathy	1 in 2,800	< 1 in 1,000,000
Glutaric Acidemia Type 1	1 in 10,000	< 1 in 1,000,000
Glycogen Storage Disease Type Ia	1 in 18,000	< 1 in 1,000,000
Glycogen Storage Disease Type Ib	1 in 35,000	< 1 in 1,000,000
Glycogen Storage Disease Type III	1 in 16,000	< 1 in 1,000,000
GNPTAB-related Disorders	1 in 32,000	< 1 in 1,000,000
GRACILE Syndrome	< 1 in 50,000	< 1 in 1,000,000
HADHA-related Disorders	1 in 15,000	< 1 in 1,000,000
Hb Beta Chain-related Hemoglobinopathy (Including Beta Thalassemia and Sickle Cell Disease)	1 in 5,000	1 in 990,000
Hereditary Fructose Intolerance	1 in 8,000	< 1 in 1,000,000
Herlitz Junctional Epidermolysis Bullosa, LAMA3-related	< 1 in 50,000	< 1 in 1,000,000
Herlitz Junctional Epidermolysis Bullosa, LAMB3-related	< 1 in 50,000	< 1 in 1,000,000
Herlitz Junctional Epidermolysis Bullosa, LAMC2-related	< 1 in 50,000	< 1 in 1,000,000
Hexosaminidase A Deficiency (Including Tay-Sachs Disease)	1 in 30,000	< 1 in 1,000,000
HMG-CoA Lyase Deficiency	< 1 in 33,000	< 1 in 1,000,000
Holocarboxylase Synthetase Deficiency	1 in 15,000	< 1 in 1,000,000
Homocystinuria Caused by Cystathionine Beta-synthase Deficiency	1 in 25,000	< 1 in 1,000,000
Hydrolethalus Syndrome	< 1 in 50,000	< 1 in 1,000,000
Hypophosphatasia, Autosomal Recessive	1 in 16,000	< 1 in 1,000,000
Inclusion Body Myopathy 2	< 1 in 50,000	< 1 in 1,000,000
Isovaleric Acidemia	1 in 25,000	< 1 in 1,000,000
Joubert Syndrome 2	< 1 in 50,000	< 1 in 1,000,000
KCNJ11-related Familial Hyperinsulinism	< 1 in 50,000	< 1 in 1,000,000
Krabbe Disease	1 in 15,000	< 1 in 1,000,000
LAMA2-related Muscular Dystrophy	1 in 34,000	< 1 in 1,000,000
Leigh Syndrome, French-Canadian Type	< 1 in 50,000	< 1 in 1,000,000
Lipoamide Dehydrogenase Deficiency	< 1 in 50,000	< 1 in 1,000,000
Lipoid Congenital Adrenal Hyperplasia	< 1 in 50,000	< 1 in 1,000,000
Lysosomal Acid Lipase Deficiency	1 in 18,000	< 1 in 1,000,000
Maple Syrup Urine Disease Type 1B	1 in 25,000	< 1 in 1,000,000
Maple Syrup Urine Disease Type Ia	1 in 42,000	< 1 in 1,000,000
Maple Syrup Urine Disease Type II	1 in 13,000	< 1 in 1,000,000
Medium Chain Acyl-CoA Dehydrogenase Deficiency	1 in 5,900	< 1 in 1,000,000
Megalencephalic Leukoencephalopathy with Subcortical Cysts		
• • • • • •	< 1 in 50,000	< 1 in 1,000,000
Metachromatic Leukodystrophy Methodomic Asidomic shift Time	1 in 20,000	< 1 in 1,000,000
Methylmalonic Acidemia, cblA Type	< 1 in 50,000	< 1 in 1,000,000
Methylmalonic Acidemia, cblB Type	1 in 48,000	< 1 in 1,000,000
Methylmalonic Aciduria and Homocystinuria, cblC Type	1 in 16,000	< 1 in 1,000,000
MKS1-related Disorders	< 1 in 50,000	< 1 in 1,000,000
Mucolipidosis III Gamma	< 1 in 50,000	< 1 in 1,000,000
Mucolipidosis IV	< 1 in 50,000	< 1 in 1,000,000



RESULTS RECIPIENT SEATTLE SPERM BANK Attn: Dr. Jeffrey Olliffe **NPI:** 1306838271 Report Date: 09/05/2018 MALE **DONOR 12361** 

DOB:

Ethnicity: Mixed or Other Caucasian

Barcode: 11004212280599

FEMALE N/A

Disease   Residual Risk   Risk   Mucopolysaccharidosis Type   1   11   16000   11   100000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   10000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   10000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   1000000   11   100000000		DONOR 12361	Reproductive
Mucophysaccharidosis Type III	Disease		
Mucopplysaccharidosis Type IIIB	Mucopolysaccharidosis Type I	1 in 16,000	< 1 in 1,000,000
Mucopplysaccharidosis Type IIIB	Mucopolysaccharidosis Type II	1 in 600,000	1 in 150,000
Mucophysaccharidosis Type IIC	Mucopolysaccharidosis Type IIIA	1 in 12,000	< 1 in 1,000,000
Muscle-ey-brain Disease			< 1 in 1,000,000
MUT-related Methylmalonic Acidemia			
MOZIA-ested Disorders	•		
NEB-related Nemaline Myopathy	·		
Nephrotic Syndrome, NPIS2-related			
Niemann-Pick Disease Type C			
Nemann-Pick Disease Type C2			
Niemann-Pick Disease, SMPD1-associated		•	
Nimegen Breakage Syndrome			
Norther Epilepsy	·		
Ornithine Transcarbamylase Deficiency         1 in 1,000,000         1 in 1,000,000           PCCA-related Propionic Acidemia         1 in 2,2000         <1 in 1,000,000           PCCH-elated Propionic Acidemia         1 in 2,2000         <1 in 1,000,000           PCDHS-Frelated Disorders         1 in 7,000         <1 in 1,000,000           Perclasted Elogenesis Disorder Type 3         1 in 4,000         <1 in 1,000,000           Percuisome Biogenesis Disorder Type 4         1 in 9,300         <1 in 1,000,000           Percuisome Biogenesis Disorder Type 5         <1 in 71,000         <1 in 1,000,000           Percuisome Biogenesis Disorder Type 6         1 in 5,000         <1 in 1,000,000           Percuisome Biogenesis Disorder Type 6         1 in 5,000         <1 in 1,000,000           Percuisome Biogenesis Disorder Type 6         1 in 1,000         <1 in 1,000,000           Percuisome Biogenesis Disorder Type 6         1 in 1,000         <1 in 1,000,000           Percuisome Biogenesis Disorder Type 6         1 in 1,000         <1 in 1,000,000           Percuisome Biogenesis Disorder Type 6         1 in 1,000         <1 in 1,000,000           PEXT-related Zelloweger Syndrome Spectrum         1 in 11,000         <1 in 1,000,000           PEXT-related Zelloweger Syndrome Spectrum         1 in 1,1000         <1 in 1,000,000           Pollogl	, , ,		
PCCA-related Propionic Acidemia			
PCCB-telated Propionic Acidemia			
PCDH15-related Disorders	·		
Pendred Syndrome			
Peroxistome Biogenesis Disorder Type 3			
Peroxistome Biogenesis Disorder Type 4			· · ·
Peroxisome Biogenesis Disorder Type 5			
Peroxisome Biogenesis Disorder Type 6	· · · · · · · · · · · · · · · · · · ·		
PEXT-related Zellweger Syndrome Spectrum         1 in 11,000         -1 in 1,000,000           Phenylalanine Hydroxylase Deficiency         1 in 5,000         -1 in 990,000           PKHD1-related Autosomal Recessive Polycystic Kidney Disease         1 in 6,100         -1 in 1,000,000           Pompe Disease         1 in 16,300         -1 in 1,000,000           PPT1-related Neuronal Ceroid Lipofuscinosis         -1 in 50,000         -1 in 1,000,000           PPT1-related Neuronal Ceroid Lipofuscinosis         -1 in 50,000         -1 in 1,000,000           Primary Hyperoxaluria Type 1         1 in 135,000         -1 in 1,000,000           Primary Hyperoxaluria Type 2         -1 in 50,000         -1 in 1,000,000           Primary Hyperoxaluria Type 3         1 in 13,000         -1 in 1,000,000           Primary Hyperoxaluria Type 3         1 in 15,000         -1 in 1,000,000           Primary Hyperoxaluria Type 3         1 in 15,000         -1 in 1,000,000           Primary Hyperoxaluria Type 3         1 in 15,000         -1 in 1,000,000           Primary Hyperoxaluria Type 3         1 in 15,000         -1 in 1,000,000           Primary Hyperoxaluria Type 3         1 in 11,000         -1 in 1,000,000           Primary Hyperoxaluria Type 3         1 in 11,000         -1 in 1,000,000           Primary Hyperoxaluria Type 3         1 in 1			
Phenylalanine Hydroxylase Deficiency			
PKHD1-related Autosomal Recessive Polycystic Kidney Disease			
Polyglandular Autoimmune Syndrome Type 1         1 in 14,000         <1 in 1,000,000           Pompe Disease         1 in 6,300         <1 in 1,000,000           PFTT-related Neuronal Ceroid Lipofuscinosis         <1 in 5,000         <1 in 1,000,000           Primary Tarnitine Deficiency         1 in 11,000         <1 in 1,000,000           Primary Hyperoxaluria Type 1         1 in 15,000         <1 in 1,000,000           Primary Hyperoxaluria Type 2         <1 in 50,000         <1 in 1,000,000           Primary Hyperoxaluria Type 3         1 in 11,000         <1 in 1,000,000           PROP1-related Combined Pituitary Hormone Deficiency         1 in 11,000         <1 in 1,000,000           Pycrovate Carboxylase Deficiency         1 in 16,000         <1 in 1,000,000           Pyruvate Carboxylase Deficiency         1 in 16,000         <1 in 1,000,000           Rhizomelic Chondrodysplasia Punctata Type 1         1 in 16,000         <1 in 1,000,000           RTEL1-related Disorders         <1 in 50,000         <1 in 1,000,000           Salla Disease         <1 in 50,000         <1 in 1,000,000           Saguar Syndrome         1 in 1,000,000         <1 in 1,000,000           Segawa Syndrome         1 in 1,000,000         <1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 1,000,000         <1 i			
Pompe Disease         1 in 6,300         < 1 in 1,000,000           PPT1-related Neuronal Ceroid Lipofuscinosis         < 1 in 50,000         < 1 in 1,000,000           Primary Large Carnitine Deficiency         1 in 11,000         < 1 in 1,000,000           Primary Hyperoxaluria Type 1         1 in 35,000         < 1 in 1,000,000           Primary Hyperoxaluria Type 2         1 in 13,000         < 1 in 1,000,000           Primary Hyperoxaluria Type 3         1 in 13,000         < 1 in 1,000,000           PROP1-related Combined Pituitary Hormone Deficiency         1 in 11,000         < 1 in 1,000,000           Pycnodysostosis         4 1 in 50,000         < 1 in 1,000,000           Pyroudysostosis         1 in 16,000         < 1 in 1,000,000           Pyroudysostosis         1 in 16,000         < 1 in 1,000,000           RTEL1-related Disorders         1 in 16,000         < 1 in 1,000,000           RTEL1-related Disorders         1 in 30,000         < 1 in 1,000,000           Salla Disease         1 in 30,000         < 1 in 1,000,000           Salla Disease         1 in 30,000         < 1 in 1,000,000           Segawa Syndrome         1 in 16,000         < 1 in 1,000,000           Short Chain Acyl-Coa Dehydrogenase Deficiency         1 in 16,000         < 1 in 1,000,000           Siggera-Larsaso Sy			
PPTI-elated Neuronal Ceroid Lipofuscinosis         < 1 in 5,0,000         < 1 in 1,000,000           Primary Carnitine Deficiency         1 in 11,000         < 1 in 1,000,000           Primary Hyperoxaluria Type 1         1 in 35,000         < 1 in 1,000,000           Primary Hyperoxaluria Type 2         < 1 in 50,000         < 1 in 1,000,000           Primary Hyperoxaluria Type 3         1 in 11,000         < 1 in 1,000,000           PROP1-related Combined Pituitary Hormone Deficiency         1 in 15,000         < 1 in 1,000,000           Pycnodysostosis         < 1 in 50,000         < 1 in 1,000,000           Pyruvate Carboxylase Deficiency         1 in 16,000         < 1 in 1,000,000           Rhizomelic Chondrodysplasia Punctata Type 1         1 in 16,000         < 1 in 1,000,000           RTEL1-related Disorders         < 1 in 50,000         < 1 in 1,000,000           Salla Disease         < 1 in 32,000         < 1 in 1,000,000           Sagawa Syndrome         < 1 in 50,000         < 1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 16,000         < 1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 16,000         < 1 in 1,000,000           Spastic Paraplegia Type 15         < 1 in 50,000         < 1 in 1,000,000           Spastic Paraplegia Type 15         < 1			
Primary Carnitine Deficiency         1 in 1,000         < 1 in 1,000,000           Primary Hyperoxaluria Type 1         1 in 35,000         < 1 in 1,000,000           Primary Hyperoxaluria Type 2         < 1 in 5,000         < 1 in 1,000,000           Primary Hyperoxaluria Type 3         1 in 13,000         < 1 in 1,000,000           PROP1-related Combined Pituitary Hormone Deficiency         1 in 10,000         < 1 in 1,000,000           Pycnodysostosis         1 in 15,000         < 1 in 1,000,000           Pyruvate Carboxylase Deficiency         1 in 25,000         < 1 in 1,000,000           Pyruvate Carboxylase Deficiency         1 in 15,000         < 1 in 1,000,000           RTEL1-related Disorders         1 in 15,000         < 1 in 1,000,000           RRIZE1-related Disorders         1 in 30,000         < 1 in 1,000,000           Salla Disease         1 in 30,000         < 1 in 1,000,000           Salla Disease         1 in 30,000         < 1 in 1,000,000           Segawa Syndrome         1 in 50,000         < 1 in 1,000,000           Segawa Syndrome         1 in 9,000         < 1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 9,000         < 1 in 1,000,000           Siggere-Larsson Syndrome         1 in 9,000         < 1 in 1,000,000           Shati-Lemli-O	•		
Primary Hyperoxaluria Type 1         1 in 35,000         < 1 in 1,000,000           Primary Hyperoxaluria Type 2         < 1 in 50,000         < 1 in 1,000,000           Primary Hyperoxaluria Type 3         1 in 13,000         < 1 in 1,000,000           PROP1-related Combined Pituitary Hormone Deficiency         1 in 11,000         < 1 in 1,000,000           Pycnodysostosis         < 1 in 50,000         < 1 in 1,000,000           Pyruvate Carboxylase Deficiency         1 in 15,000         < 1 in 1,000,000           Rhizomelic Chondrodysplasia Punctata Type 1         1 in 16,000         < 1 in 1,000,000           RREL1-related Disorders         < 1 in 50,000         < 1 in 1,000,000           Salla Disease         1 in 32,000         < 1 in 1,000,000           Sagawa Syndrome         1 in 16,000         < 1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 16,000         < 1 in 1,000,000           Sigen-Larsson Syndrome         1 in 9,100         < 1 in 1,000,000           Smith-Lemli-Opitz Syndrome         1 in 9,100         < 1 in 1,000,000           Smith-Lemli-Opitz Syndrome         Negative for g.27134T>G SNP           Spinal Muscular Atrophy         Negative for g.27134T>G SNP           Spinal Muscular Atrophy         1 in 15,000         < 1 in 1,000,000           Total Trelated			
Primary Hyperoxaluria Type 2         <1 in 50,000         <1 in 1,000,000           Primary Hyperoxaluria Type 3         1 in 13,000         <1 in 1,000,000           PROP1-related Combined Pituitary Hormone Deficiency         1 in 1,000         <1 in 1,000,000           Pycnodysostosis         <1 in 50,000         <1 in 1,000,000           Pyruvate Carboxylase Deficiency         1 in 25,000         <1 in 1,000,000           Rhizomelic Chondrodysplasia Punctata Type 1         1 in 16,000         <1 in 1,000,000           RTEL1-related Disorders         <1 in 50,000         <1 in 1,000,000           Salla Disease         <1 in 30,000         <1 in 1,000,000           Salla Disease         1 in 30,000         <1 in 1,000,000           Segawa Syndrome         1 in 16,000         <1 in 1,000,000           Segawa Syndrome         1 in 16,000         <1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 16,000         <1 in 1,000,000           Sfoggren-Larsson Syndrome         1 in 9,100         <1 in 1,000,000           Spastic Paraplegia Type 15         1 in 50,000         <1 in 1,000,000           Spastic Paraplegia Type 15         1 in 70,000         <1 in 1,000,000           Spinal Muscular Atrophy         Smothylate Cale Cale Cale Cale Cale Cale Cale Cal			
Primary Hyperoxaluria Type 3         1 in 13,000         <1 in 1,000,000           PROP1-related Combined Pituitary Hormone Deficiency         1 in 11,000         <1 in 1,000,000           Pycnodysostosis         <1 in 50,000         <1 in 1,000,000           Pyruvate Carboxylase Deficiency         1 in 25,000         <1 in 1,000,000           Rhizomelic Chondrodysplasia Punctata Type 1         1 in 16,000         <1 in 1,000,000           STEL1-related Disorders         <1 in 50,000         <1 in 1,000,000           Salla Disease         <1 in 30,000         <1 in 1,000,000           Sagawa Syndrome         <1 in 50,000         <1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 16,000         <1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 16,000         <1 in 1,000,000           Sinth-Lemil-Opitz Syndrome         1 in 9,100         <1 in 1,000,000           Sinth-Lemil-Opitz Syndrome         1 in 50,000         <1 in 1,000,000           Spastic Paraplegia Type 15         <1 in 50,000         <1 in 1,000,000           Spondylothoracic Dysostosis         <1 in 50,000         <1 in 1,000,000           Spondylothoracic Dysostosis         <1 in 50,000         <1 in 1,000,000           SUlfate Transporter-related Osteochondrodysplasia         1 in 1,000			
PROP1-related Combined Pituitary Hormone Deficiency         1 in 11,000         <1 in 1,000,000           Pycnodysostosis         <1 in 50,000         <1 in 1,000,000           Pytruvate Carboxylase Deficiency         1 in 25,000         <1 in 1,000,000           Rhizomelic Chondrodysplasia Punctata Type 1         1 in 16,000         <1 in 1,000,000           RTE11-related Disorders         <1 in 50,000         <1 in 1,000,000           Salla Disease         <1 in 30,000         <1 in 1,000,000           Salla Disease         1 in 32,000         <1 in 1,000,000           Segawa Syndrome         <1 in 50,000         <1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 16,000         <1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 9,100         <1 in 1,000,000           Siggere-Larsson Syndrome         1 in 9,100         <1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 50,000         <1 in 1,000,000           Smith-Lemli-Opitz Syndrome         1 vS8-1G>C heterozygote 1         1 in 200           Spastic Paraplegia Type 15         <1 in 50,000         <1 in 1,000,000           Spinal Muscular Atrophy         SMN1: 2 copies         1 in 11,000,000           Spondylothoracic Dysostosis         1 in 50,000         <1 in 1,000,			
Pycnodysostosis         < 1 in 50,000         < 1 in 1,000,000           Pyruvate Carboxylase Deficiency         1 in 25,000         < 1 in 1,000,000           Rhizomelic Chondrodysplasia Punctata Type 1         1 in 16,000         < 1 in 1,000,000           RTEL1-related Disorders         < 1 in 50,000         < 1 in 1,000,000           Salla Disease         1 in 32,000         < 1 in 1,000,000           Segawa Syndrome         < 1 in 50,000         < 1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 16,000         < 1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 9,100         < 1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 9,100         < 1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 50,000         < 1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 50,000         < 1 in 1,000,000           Spastic Paraplegia Type 15         < 1 in 50,000         < 1 in 1,000,000           Spinal Muscular Atrophy         SMN1: 2 copies         1 in 11,000           Spinal Muscular Atrophy         SMN1: 2 copies         1 in 11,000           Spinal Muscular Atrophy         SMN1: 2 copies         1 in 1,000,000           Sulfate Transporter-related Osteochondrodysplasia			
Pyruvate Carboxylase Deficiency         1 in 25,000         < 1 in 1,000,000           Rhizomelic Chondrodysplasia Punctata Type 1         1 in 16,000         < 1 in 1,000,000           STETL1-related Disorders         < 1 in 50,000         < 1 in 1,000,000           Salla Disease         < 1 in 30,000         < 1 in 1,000,000           Sandhoff Disease         1 in 32,000         < 1 in 1,000,000           Segawa Syndrome         < 1 in 50,000         < 1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 16,000         < 1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 9,100         < 1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 9,000         < 1 in 1,000,000           Sport Chain Acyl-CoA Dehydrogenase Deficiency         1 in 9,000         < 1 in 1,000,000           Sport Chain Acyl-CoA Dehydrogenase Deficiency         1 in 9,000         < 1 in 1,000,000           Sport Chain Acyl-CoA Dehydrogenase Deficiency         1 in 9,000         < 1 in 1,000,000           Sport Graph Chain Acyl-CoA Dehydrogenase Deficiency         1 in 10,000         < 1 in 1,000,000           Sport Graph Chain Acyl-CoA Dehydrogenase Deficiency         1 in 1,000         < 1 in 1,000,000           Sport Graph Chain Acyl-CoA Dehydrogenase Deficiency         1 in 8,600         < 1 in 1,00			
Rhizomelic Chondrodysplasia Punctata Type 1         1 in 16,000         <1 in 1,000,000           RTE1-related Disorders         <1 in 50,000         <1 in 1,000,000           Salla Disease         <1 in 30,000         <1 in 1,000,000           Sandhoff Disease         1 in 32,000         <1 in 1,000,000           Segawa Syndrome         <1 in 50,000         <1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 16,000         <1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 19,000         <1 in 1,000,000           Smith-Lemil-Opitz Syndrome         1 VS8-1G-C heterozygote ¹         1 in 20           Spastic Paraplegia Type 15         <1 in 50,000         <1 in 1,000,000           Negative for g.27134T>G SNP         NNS1: 2 copies         1 in 110,000           Spinal Muscular Atrophy         5MN1: 2 copies         1 in 110,000           Spinal Muscular Atrophy         5MN1: 2 copies         1 in 110,000           Sulfate Transporter-related Osteochondrodysplasia         1 in 150,000         <1 in 1,000,000           Sulfate Transporter-related Osteochondrodysplasia         1 in 12,000         <1 in 1,000,000           TPP1-related Neuronal Ceroid Lipofuscinosis         1 in 30,000         <1 in 1,000,000           Tyrosinemia Type I         1 in 17,000	•		
RTEL1-related Disorders         < 1 in 50,000         < 1 in 1,000,000           Salla Disease         < 1 in 30,000         < 1 in 1,000,000           Segawa Syndrome         < 1 in 50,000         < 1 in 1,000,000           Segawa Syndrome         < 1 in 16,000         < 1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 16,000         < 1 in 1,000,000           Sjogren-Larsson Syndrome         1 in 9,100         < 1 in 1,000,000           Smith-Lemli-Opitz Syndrome         IVS8-1G-C heterozygote †         1 in 200           Spastic Paraplegia Type 15         < 1 in 50,000         < 1 in 1,000,000           Spinal Muscular Atrophy         Negative for g,27134T>G SNP           Spinal Muscular Atrophy         SMN1: 2 copies         1 in 110,000           Sulfate Transporter-related Osteochondrodysplasia         1 in 50,000         < 1 in 1,000,000           Sulfate Transporter-related Osteochondrodysplasia         1 in 11,000         < 1 in 1,000,000           TPP1-related Neuronal Ceroid Lipofuscinosis         1 in 22,000         < 1 in 1,000,000           TPP1-related Neuronal Ceroid Lipofuscinosis         1 in 17,000         < 1 in 1,000,000           Tyrosinemia Type I         1 in 17,000         < 1 in 1,000,000           Tyrosinemia Type I         1 in 22,000         < 1 in 1,000,000 </th <th></th> <th></th> <th></th>			
Salla Disease         < 1 in 30,000         < 1 in 1,000,000           Sandhoff Disease         1 in 32,000         < 1 in 1,000,000           Segawa Syndrome         < 1 in 50,000         < 1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 16,000         < 1 in 1,000,000           Sjogren-Larsson Syndrome         1 in 9,100         < 1 in 1,000,000           Smith-Lemli-Opitz Syndrome         IVS8-1G>C heterozygote †         1 in 200           Spastic Paraplegia Type 15         < 1 in 50,000         < 1 in 1,000,000           Spinal Muscular Atrophy         SMN1: 2 copies         1 in 110,000,000           Spondylothoracic Dysostosis         < 1 in 50,000         < 1 in 1,000,000           Sulfate Transporter-related Osteochondrodysplasia         1 in 11,000         < 1 in 1,000,000           TGM1-related Autosomal Recessive Congenital Ichthyosis         1 in 2,000         < 1 in 1,000,000           TPP1-related Neuronal Ceroid Lipofuscinosis         1 in 30,000         < 1 in 1,000,000           Tyrosinemia Type I         1 in 17,000         < 1 in 1,000,000           Tyrosinemia Type II         1 in 25,000         < 1 in 1,000,000           USH1C-related Disorders         1 in 3,000         < 1 in 1,000,000           USH2A-related Disorders         1 in 5,000         < 1 in 1,000,000 <th>• • • • • • • • • • • • • • • • • • • •</th> <th></th> <th></th>	• • • • • • • • • • • • • • • • • • • •		
Sandhoff Disease         1 in 32,000         < 1 in 1,000,000           Segawa Syndrome         < 1 in 50,000         < 1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 16,000         < 1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 9,100         < 1 in 1,000,000           Smith-Lemli-Opitz Syndrome         IVS8-16>C heterozygote ¹         1 in 200           Spastic Paraplegia Type 15         < 1 in 50,000         < 1 in 1,000,000           Spinal Muscular Atrophy         SMN1: 2 copies         1 in 110,000           Spinal Muscular Atrophy         SMN1: 2 copies         1 in 1,000,000           Spondylothoracic Dysostosis         < 1 in 50,000         < 1 in 1,000,000           Sulfate Transporter-related Osteochondrodysplasia         1 in 11,000         < 1 in 1,000,000           TGM1-related Autosomal Recessive Congenital Ichthyosis         1 in 22,000         < 1 in 1,000,000           TPP1-related Neuronal Ceroid Lipofuscinosis         1 in 30,000         < 1 in 1,000,000           TPYrosinemia Type I         1 in 17,000         < 1 in 1,000,000           USH1C-related Disorders         1 in 25,000         < 1 in 1,000,000           USH2A-related Disorders         1 in 35,000         < 1 in 1,000,000           Usher Syndrome Type 3         1 in 1,000,000 </th <th></th> <th></th> <th></th>			
Segawa Syndrome         < 1 in 50,000         < 1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 16,000         < 1 in 1,000,000           Sjogren-Larsson Syndrome         1 in 9,100         < 1 in 1,000,000           Smith-Lemli-Opitz Syndrome         1 vS8-1G>C heterozygote <sup>↑</sup> 1 in 200           Spastic Paraplegia Type 15         < 1 in 50,000         < 1 in 1,000,000           Negative for g.27134T>G SNP         SMN1: 2 copies         1 in 110,000           Spondylothoracic Dysostosis         < 1 in 50,000         < 1 in 1,000,000           Sulfate Transporter-related Osteochondrodysplasia         1 in 11,000         < 1 in 1,000,000           TGM1-related Autosomal Recessive Congenital Ichthyosis         1 in 22,000         < 1 in 1,000,000           TPT-related Neuronal Ceroid Lipofuscinosis         1 in 30,000         < 1 in 1,000,000           Tyrosinemia Type I         1 in 17,000         < 1 in 1,000,000           USH1C-related Disorders         1 in 25,000         < 1 in 1,000,000           USH2A-related Disorders         1 in 35,000         < 1 in 1,000,000           USH2A-related Disorders         1 in 8,000         < 1 in 1,000,000           Usher Syndrome Type 3         < 1 in 50,000         < 1 in 1,000,000           Wery Long Chain Acyl-CoA Dehydrogenase Deficiency <td< th=""><th></th><th></th><th>· · ·</th></td<>			· · ·
Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 16,000         <1 in 1,000,000           Sjogren-Larsson Syndrome         1 in 9,100         <1 in 1,000,000           Smith-Lemli-Opitz Syndrome         IVS8-1G>C heterozygote †         1 in 200           Spastic Paraplegia Type 15         <1 in 50,000         <1 in 1,000,000           Spinal Muscular Atrophy         SMN1: 2 copies         1 in 110,000           Spinal Muscular Atrophy         5MN1: 2 copies         1 in 110,000           Spondylothoracic Dysostosis         <1 in 50,000         <1 in 1,000,000           Sulfate Transporter-related Osteochondrodysplasia         1 in 11,000         <1 in 1,000,000           TGM1-related Autosomal Recessive Congenital Ichthyosis         1 in 22,000         <1 in 1,000,000           TPP1-related Neuronal Ceroid Lipofuscinosis         1 in 30,000         <1 in 1,000,000           Tyrosinemia Type I         1 in 17,000         <1 in 1,000,000           Tyrosinemia Type II         1 in 25,000         <1 in 1,000,000           Usher Crelated Disorders         1 in 35,000         <1 in 1,000,000           Usher Syndrome Type 3         <1 in 50,000         <1 in 1,000,000           Very Long Chain Acyl-CoA Dehydrogenase Deficiency         1 in 8,600         <1 in 1,000,000           Wilson Disease         1 in 90,000 <t< th=""><th></th><th></th><th></th></t<>			
Sjogren-Larsson Syndrome	· ·		
Smith-Lemli-Opitz Syndrome         IVS8-1G>C heterozygote <sup>†</sup> 1 in 200           Spastic Paraplegia Type 15         < 1 in 50,000			
Spastic Paraplegia Type 15         < 1 in 50,000         < 1 in 1,000,000           Negative for g.27134T>G SNP           Spinal Muscular Atrophy         SMN1: 2 copies 1 in 770         1 in 110,000           Spondylothoracic Dysostosis         < 1 in 50,000         < 1 in 1,000,000           Sulfate Transporter-related Osteochondrodysplasia         1 in 11,000         < 1 in 1,000,000           TGM1-related Autosomal Recessive Congenital Ichthyosis         1 in 22,000         < 1 in 1,000,000           TPP1-related Neuronal Ceroid Lipofuscinosis         1 in 30,000         < 1 in 1,000,000           Tyrosinemia Type I         1 in 17,000         < 1 in 1,000,000           USH1C-related Disorders         1 in 25,000         < 1 in 1,000,000           USH2A-related Disorders         1 in 35,000         < 1 in 1,000,000           USH2A-related Disorders         1 in 2,200         < 1 in 1,000,000           Usher Syndrome Type 3         < 1 in 50,000         < 1 in 1,000,000           Very Long Chain Acyl-CoA Dehydrogenase Deficiency         1 in 8,800         < 1 in 1,000,000           Wilson Disease         1 in 8,600         < 1 in 1,000,000           X-linked Adrenoleukodystrophy         1 in 90,000         1 in 1,000,000		•	
Negative for g.27134T>G SNP           Spinal Muscular Atrophy         SMN1: 2 copies 1 in 770           Spondylothoracic Dysostosis         <1 in 50,000	• •		
Spinal Muscular Atrophy         SMN1: 2 copies 1 in 770           Spondylothoracic Dysostosis         < 1 in 50,000			,
Spondylothoracic Dysostosis         <1 in 50,000         <1 in 1,000,000           Sulfate Transporter-related Osteochondrodysplasia         1 in 11,000         <1 in 1,000,000           TGM1-related Autosomal Recessive Congenital Ichthyosis         1 in 22,000         <1 in 1,000,000           TPP1-related Neuronal Ceroid Lipofuscinosis         1 in 30,000         <1 in 1,000,000           Tyrosinemia Type I         1 in 17,000         <1 in 1,000,000           Tyrosinemia Type II         1 in 25,000         <1 in 1,000,000           USH1C-related Disorders         1 in 35,000         <1 in 1,000,000           USH2A-related Disorders         1 in 2,200         <1 in 1,000,000           Usher Syndrome Type 3         <1 in 50,000         <1 in 1,000,000           Very Long Chain Acyl-CoA Dehydrogenase Deficiency         1 in 8,800         <1 in 1,000,000           Wilson Disease         1 in 8,600         <1 in 1,000,000           X-linked Adrenoleukodystrophy         1 in 90,000         1 in 42,000	Spinal Muscular Atrophy	-	1 in 110,000
Sulfate Transporter-related Osteochondrodysplasia       1 in 11,000       < 1 in 1,000,000         TGM1-related Autosomal Recessive Congenital Ichthyosis       1 in 22,000       < 1 in 1,000,000         TPP1-related Neuronal Ceroid Lipofuscinosis       1 in 30,000       < 1 in 1,000,000         Tyrosinemia Type I       1 in 17,000       < 1 in 1,000,000         Tyrosinemia Type II       1 in 25,000       < 1 in 1,000,000         USH1C-related Disorders       1 in 35,000       < 1 in 1,000,000         USH2A-related Disorders       1 in 2,200       < 1 in 1,000,000         Usher Syndrome Type 3       < 1 in 50,000       < 1 in 1,000,000         Very Long Chain Acyl-CoA Dehydrogenase Deficiency       1 in 8,800       < 1 in 1,000,000         Wilson Disease       1 in 8,600       < 1 in 1,000,000         X-linked Adrenoleukodystrophy       1 in 90,000       1 in 42,000		1 in 770	
TGM1-related Autosomal Recessive Congenital Ichthyosis       1 in 22,000       < 1 in 1,000,000         TPP1-related Neuronal Ceroid Lipofuscinosis       1 in 30,000       < 1 in 1,000,000         Tyrosinemia Type I       1 in 17,000       < 1 in 1,000,000         Tyrosinemia Type II       1 in 25,000       < 1 in 1,000,000         USH1C-related Disorders       1 in 35,000       < 1 in 1,000,000         USH2A-related Disorders       1 in 2,200       < 1 in 1,000,000         Usher Syndrome Type 3       < 1 in 50,000       < 1 in 1,000,000         Very Long Chain Acyl-CoA Dehydrogenase Deficiency       1 in 8,800       < 1 in 1,000,000         Wilson Disease       1 in 8,600       < 1 in 1,000,000         X-linked Adrenoleukodystrophy       1 in 90,000       1 in 42,000	Spondylothoracic Dysostosis	< 1 in 50,000	< 1 in 1,000,000
TPP1-related Neuronal Ceroid Lipofuscinosis       1 in 30,000       < 1 in 1,000,000         Tyrosinemia Type I       1 in 17,000       < 1 in 1,000,000         Tyrosinemia Type II       1 in 25,000       < 1 in 1,000,000         USH1C-related Disorders       1 in 35,000       < 1 in 1,000,000         USH2A-related Disorders       1 in 2,200       < 1 in 1,000,000         Usher Syndrome Type 3       < 1 in 50,000       < 1 in 1,000,000         Very Long Chain Acyl-CoA Dehydrogenase Deficiency       1 in 8,800       < 1 in 1,000,000         Wilson Disease       1 in 8,600       < 1 in 1,000,000         X-linked Adrenoleukodystrophy       1 in 90,000       1 in 42,000	Sulfate Transporter-related Osteochondrodysplasia	1 in 11,000	< 1 in 1,000,000
Tyrosinemia Type I       1 in 17,000       < 1 in 1,000,000         Tyrosinemia Type II       1 in 25,000       < 1 in 1,000,000         USH1C-related Disorders       1 in 35,000       < 1 in 1,000,000         USH2A-related Disorders       1 in 2,200       < 1 in 1,000,000         Usher Syndrome Type 3       < 1 in 50,000       < 1 in 1,000,000         Very Long Chain Acyl-CoA Dehydrogenase Deficiency       1 in 8,800       < 1 in 1,000,000         Wilson Disease       1 in 8,600       < 1 in 1,000,000         X-linked Adrenoleukodystrophy       1 in 90,000       1 in 42,000	TGM1-related Autosomal Recessive Congenital Ichthyosis	1 in 22,000	< 1 in 1,000,000
Tyrosinemia Type II       1 in 25,000       < 1 in 1,000,000         USH1C-related Disorders       1 in 35,000       < 1 in 1,000,000         USH2A-related Disorders       1 in 2,200       < 1 in 1,000,000         Usher Syndrome Type 3       < 1 in 50,000       < 1 in 1,000,000         Very Long Chain Acyl-CoA Dehydrogenase Deficiency       1 in 8,800       < 1 in 1,000,000         Wilson Disease       1 in 8,600       < 1 in 1,000,000         X-linked Adrenoleukodystrophy       1 in 90,000       1 in 42,000	TPP1-related Neuronal Ceroid Lipofuscinosis	1 in 30,000	< 1 in 1,000,000
USH1C-related Disorders       1 in 35,000       < 1 in 1,000,000         USH2A-related Disorders       1 in 2,200       < 1 in 1,000,000         Usher Syndrome Type 3       < 1 in 50,000       < 1 in 1,000,000         Very Long Chain Acyl-CoA Dehydrogenase Deficiency       1 in 8,800       < 1 in 1,000,000         Wilson Disease       1 in 8,600       < 1 in 1,000,000         X-linked Adrenoleukodystrophy       1 in 90,000       1 in 42,000	Tyrosinemia Type I	1 in 17,000	< 1 in 1,000,000
USH2A-related Disorders       1 in 2,200       <1 in 1,000,000         Usher Syndrome Type 3       <1 in 50,000       <1 in 1,000,000         Very Long Chain Acyl-CoA Dehydrogenase Deficiency       1 in 8,800       <1 in 1,000,000         Wilson Disease       1 in 8,600       <1 in 1,000,000         X-linked Adrenoleukodystrophy       1 in 90,000       1 in 42,000	Tyrosinemia Type II	1 in 25,000	< 1 in 1,000,000
Usher Syndrome Type 3       < 1 in 50,000       < 1 in 1,000,000         Very Long Chain Acyl-CoA Dehydrogenase Deficiency       1 in 8,800       < 1 in 1,000,000         Wilson Disease       1 in 8,600       < 1 in 1,000,000         X-linked Adrenoleukodystrophy       1 in 90,000       1 in 42,000	USH1C-related Disorders	1 in 35,000	< 1 in 1,000,000
Very Long Chain Acyl-CoA Dehydrogenase Deficiency         1 in 8,800         < 1 in 1,000,000           Wilson Disease         1 in 8,600         < 1 in 1,000,000           X-linked Adrenoleukodystrophy         1 in 90,000         1 in 42,000	USH2A-related Disorders	1 in 2,200	< 1 in 1,000,000
Wilson Disease         1 in 8,600         < 1 in 1,000,000           X-linked Adrenoleukodystrophy         1 in 90,000         1 in 42,000	•	< 1 in 50,000	
<b>X-linked Adrenoleukodystrophy</b> 1 in 90,000 1 in 42,000	Very Long Chain Acyl-CoA Dehydrogenase Deficiency	1 in 8,800	< 1 in 1,000,000
· · · · ·		1 in 8,600	< 1 in 1,000,000
X-linked Alport Syndrome Not calculated Not calculated	X-linked Adrenoleukodystrophy		1 in 42,000
	X-linked Alport Syndrome	Not calculated	Not calculated



Report Date: 09/05/2018

MALE

DONOR 12361

DOB

Ethnicity: Mixed or Other

Caucasian

Barcode: 11004212280599

FEMALE N/A

DONOR 12361 Residual Risk	Reproductive Risk
< 1 in 1,000,000	< 1 in 1,000,000
< 1 in 1,000,000	1 in 50,000
Not calculated	Not calculated
< 1 in 1,000,000	1 in 200,000
< 1 in 50,000	< 1 in 1,000,000
1 in 7,300	< 1 in 1,000,000
	Residual Risk < 1 in 1,000,000 < 1 in 1,000,000 Not calculated < 1 in 1,000,000 < 1 in 50,000